Merck & Co Inc (MRK)

62.15
0.81 1.29
NYSE : Health Care
Prev Close 62.96
Open 62.55
Day Low/High 61.88 / 62.58
52 Wk Low/High 47.97 / 64.00
Volume 6.93M
Avg Volume 9.79M
Exchange NYSE
Shares Outstanding 2.77B
Market Cap 174.26B
EPS 1.60
P/E Ratio 34.63
Div & Yield 1.84 (2.90%)

Latest News

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

Takeover Chatter Around Clovis May Be Overdone

Takeover Chatter Around Clovis May Be Overdone

Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.

Merck To Hold Third-Quarter 2016 Sales And Earnings Conference Call On October 25

Merck To Hold Third-Quarter 2016 Sales And Earnings Conference Call On October 25

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

5 Dividend Stocks That Want to Pay You More Money

5 Dividend Stocks That Want to Pay You More Money

These dividend stocks are poised to increase their payouts to shareholders soon.

Merck To Host Investor Teleconference To Discuss ESMO 2016 Highlights

Merck To Host Investor Teleconference To Discuss ESMO 2016 Highlights

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in...

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

U.S. stock futures point higher as oil prices rally; Canada's autoworkers' union and GM make little progress in contract talks ahead of a Monday deadline.

Merck (MRK) Stock Higher, Joint Pfizer Diabetes Drug Meets Primary Endpoint

Merck (MRK) Stock Higher, Joint Pfizer Diabetes Drug Meets Primary Endpoint

Merck (MRK) and Pfizer's (PFE) diabetes treatment met its primary endpoint in a Phase III trial.

Big Pharma Spends Millions to Keep Prices High for California Agencies

Big Pharma Spends Millions to Keep Prices High for California Agencies

Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.

Merck Publishes 2015/2016 Global Corporate Responsibility Report

Merck Publishes 2015/2016 Global Corporate Responsibility Report

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2015/2016 global corporate responsibility report.

Pet Pharma Is the Newest Growth Sector

Pet Pharma Is the Newest Growth Sector

Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Upcoming Dividend Must-Own Dates

From Altria to Western Union, these 21 companies have must-own dates over the next week.

Merck To Participate At The Morgan Stanley Global Healthcare Conference

Merck To Participate At The Morgan Stanley Global Healthcare Conference

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Will Merck (MRK) Stock Be Helped by FDA Lung Cancer Drug Review?

Will Merck (MRK) Stock Be Helped by FDA Lung Cancer Drug Review?

Merck's (MRK) lung cancer drug, called Keytruda, was given breakthrough therapy status by the FDA.

Merck to Discontinue Osteoporosis Drug Development

Merck to Discontinue Osteoporosis Drug Development

Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.

Will Merck (MRK) Stock Be Hurt by Discontinuing Osteoporosis Drug Development?

Will Merck (MRK) Stock Be Hurt by Discontinuing Osteoporosis Drug Development?

Merck (MRK) will no longer develop its osteoporosis treatment due to an increased risk of stroke.

Merck Provides Update On Odanacatib Development Program

Merck Provides Update On Odanacatib Development Program

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck's investigational cathepsin K inhibitor for osteoporosis, and will not seek...

Top 10 Dividend Stocks to Buy in September

Top 10 Dividend Stocks to Buy in September

Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.

Will Merck (MRK) Stock Be Helped by Bullish Bernstein Note?

Will Merck (MRK) Stock Be Helped by Bullish Bernstein Note?

Merck (MRK) could remain the leader in lung cancer treatments depending on how it 'plays its hand,' Bernstein said in a note Wednesday.

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.

Intermediate Trade: Merck

Intermediate Trade: Merck

The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.

Cramer: The 'Just You Wait' Crowd Keeps Waiting

Cramer: The 'Just You Wait' Crowd Keeps Waiting

The market continues to defy those players who believe we are seeing the calm before the storm.

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors

The FDA approved Merck's Keytruda, a drug to treat metastatic and recurrent cancer.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.